tbuckley/cabot-search huggingface dataset:
MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation
Authors: Tiantian Wang, Dean Rao, Chenan Fu, Zhoubin Sun, Yiming Luo, Junli Lu, Jie Jin, Han Li, Feimu Fan, Huifang Liang, Wenjie Huang, Limin Xia
Journal: Clinical and Molecular Hepatology (2025)

Hepatocellular carcinoma (HCC) is a highly heterogeneous disease, and abnormal MET expression plays a crucial role in its progression. However, the specific pathogenic mechanisms of MET in HCC have yet to be fully elucidated. This study aimed to uncover the oncogenic mechanisms of MET in HCC and explore potential therapeutic implications. Transcriptomic data from the HTVi MET/β-catenin HCC model and GSEA results from TCGA LIHC cohorts were analyzed to identify key genes in HCC development. In vitro assays and in vivo models were used to investigate the role of TRIB3 in HCC progression. Immunofluorescence (IF), Co-IP, qRT-PCR, and WB revealed target genes regulated by TRIB3. An AAV8-shTRIB3 construct was developed and we assessed its therapeutic potential. MET promoted HCC development both in vitro and in vivo by upregulating the oncogenic protein TRIB3. Mechanistically, MET transcriptionally activated TRIB3 via the ERK/SP1 axis. TRIB3 then recruited the E3 ubiquitin ligase COP1, which facilitated the ubiquitination and degradation of the tumor suppressor transcription factor FOXO1. TRIB3-mediated FOXO1 ubiquitination up regulated the expression of MET, CTNNB1 and TWIST1. In clinical HCC samples, TRIB3 expression was correlated with MET and FOXO1 levels. Liver-specific knockdown of TRIB3 by AAV8-shTRIB3 significantly inhibited MET-driven HCC development. Our results revealed that TRIB3 and COP1 act as key mediators in MET-driven HCC progression. Targeting the MET-TRIB3-FOXO1 regulatory axis may offer a promising therapeutic strategy to counteract oncogenic signaling and impede HCC advancement.
All genetic subtypes of B-cell acute lymphoblastic leukemia exhibit increased incidence rates in children with Down syndrome
Authors: Ching-Ju Hsu, Jeremy M Schraw, Tania A Desrosiers, Amanda E Janitz, Russell S Kirby, Eirini Nestoridi, Wendy N Nembhard, Jason L Salemi, Charles Shumate, Jean Paul Tanner, Mahsa M Yazdy, Michael E Scheurer, Karen R Rabin, Philip J Lupo
Journal: Leukemia (2025)
Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States
Authors: Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G Singal, Ju Dong Yang
Journal: Clinical and Molecular Hepatology (2025)

Harmful alcohol use is a substantial contributor to liver diseases, liver cancer, and extrahepatic neoplasms. Patterns of alcohol consumption have shifted over recent decades. This study evaluates trends in alcohol-associated liver disease (ALD) and alcohol-attributable cancers in the United States (US) from 2000 to 2021. Using the methodological framework of the Global Burden of Disease Study 2021, we analyzed trends in incidence, prevalence, and mortality from ALD and alcohol-attributable cancers in the US. In 2021, there were 28,340 new cases of ALD, 227,730 prevalent cases, and 21,860 deaths attributed to ALD in the USA. From 2000 to 2021, ALD incidence, prevalence, and mortality increased by 43%, 36%, and 79%, respectively. The age-standardized incidence and death rate of ALD rose disproportionately among females compared to males. For alcohol-attributable cancers, primary liver cancer, colorectal cancer, and esophageal cancer accounted for the largest share of deaths in 2021. Age-standardized death rates increased significantly for primary liver cancer (Annual Percent Change [APC]: 2.21%, 95% CI: 1.70 to 2.73% and other pharyngeal cancer (APC: 1.35%, 95% CI: 1.08 to 1.62%). The burden of ALD is substantial and continues to rise in the USA, with a particularly notable increase among females. Mortality from alcohol-attributable cancers is also increasing, mainly driven by primary liver cancer and pharyngeal cancer. However, system-wise, gastrointestinal cancer had the highest death attributable to alcohol. These findings highlight the urgent need for public health strategies to tackle ALD, primary liver cancer, and alcohol-attributable extrahepatic malignancies.
Neutrophil extracellular traps associated <scp>RNA</scp> impedes <scp>CD4</scp><sup>+</sup> Treg differentiation by <scp>TLR7</scp>‐<scp>IRF7</scp> axis in ankylosing spondylitis
Authors: Zhikun Li, Jiajie Lin, Zepeng Su, Yipeng Zeng, Yi Zhou, Jinteng Li, Wenhui Yu, Guiwen Ye, Guan Zheng, Zipeng Xiao, Yanfeng Wu, Huiyong Shen, Zhongyu Xie
Journal: Arthritis & Rheumatology (2025)

Objective To investigate the role of neutrophil extracellular traps (NETs) in the pathogenesis of inflammatory disorders in ankylosing spondylitis (AS). Methods Local and circulating NETs levels were determined by immunofluorescence (IF) and MPO‐DNA quantification in both AS patients and AS model SKG mice. Flow cytometry (FCM) was performed to detect the effect of NETs on CD4 + subpopulation differentiation. The therapeutic effects of the neutrophil elastase inhibitor sivelestat (SVT) and the PAD4 inhibitor CI‐amidine were evaluated in SKG mice. The localization of NETs and their ability to impede CD4 + regulatory T (Treg) cell differentiation were evaluated via IF, FCM and western blotting. RNA sequencing and specific inhibitors were used to clarify the detailed mechanism by which NETs inhibit CD4 + Treg differentiation. Results The NETs levels were elevated locally and systemically in both AS patients and SKG mice, which impeded the differentiation of CD4 + Treg. Blocking NETs formation via SVT or CI‐amidine restored the CD4 + Treg ratio and subsequently alleviated inflammation in SKG mice. NETs were internalized by CD4 + T cells, and their associated RNA activated the TLR7–IRF7 axis, which then inhibited Treg differentiation. Inhibiting CD4 + T cells endocytosis, removing the bound RNA component or blocking the TLR7–IRF7 axis abrogated the negative effect of NETs on CD4 + Treg differentiation. Conclusion Elevated NETs impeded CD4 + Treg differentiation by activating the TLR7–IRF7 axis via their associated RNA in AS, and targeting NETs may be a novel treatment strategy for AS and related inflammatory disorders. image
Participation and yield of gastric cancer screening programs: A systematic review and meta-analysis
Authors: Jiayue Wang, Xianzhu Zhou, Huiyun Zhu, Wenbo Zhu, Zhantong Wang, Shengyong Wu, Shihan Xu, Yifan Qiu, Chanjuan Wang, Zhaoshen Li, Yiqi Du
Journal: Clinical Gastroenterology and Hepatology (2025)
All-cause and cause-specific mortality in achalasia: A nationwide matched cohort study
Authors: Anders Forss, Marcus Reuterwall Hansson, Dag Holmberg, Marcus Thuresson, Fahim Ebrahimi, Peter Elbe, Fredrik Klevebro, Bengt Håkanson, Anders Thorell, Jonas F Ludvigsson
Journal: Clinical Gastroenterology and Hepatology (2025)
Global Occurrence Rates of Sleep Disturbances Among Institutionalized Older Adults: A Systematic Review and Meta-analysis
Authors: Santa Maria Pangaribuan, Tzu-Ying Wu, Risa Herlianita, Ying-Ling Jao, Hsin-Chien Lee, Faizul Hasan, Muhammad Amirul Mukminin, Hsiao-Yean Chiu
Journal: Sleep Medicine Reviews (2025)
Tumor-Derived CD109 Orchestrates Reprogramming of Tumor-Associated Macrophages to Dampen Immune Response
Authors: Tianming Cui, Linmao Sun, Xinyu Guo, Cheng Cheng, Ning Zhang, Shuo Zhou, Qi Chu, Changjian Xing, Shuhang Liang, Yufeng Liu, Changyong Ji, Xianying Li, Shengwei Tao, Xuetian Gu, Kun Ma, Chenghui Wu, Junhui Chu, Yumin Fu, Sitao Han, Yuchen Zhang, Jiareng Ye, Yao Liu, Jiabei Wang, Lianxin Liu
Journal: Journal of Hepatology (2025)
Cross-sectional, interventional, and causal investigation of insulin sensitivity using plasma proteomics in diverse populations
Authors: Pik Fang Kho, Neil Wary, Daniela Zanetti, Fahim Abbasi, Joshua W Knowles, Daniel J Panyard, Katie T Watson, Laurel Stell, Laura C Lazzeroni, Stefan Gustafsson, Lars Lind, John R Petrie, Themistocles L Assimes
Journal: Metabolism (2025)
Multifunctional albumin-based hydrogel/microglia composites enhancing the therapeutic potential of neonatal microglia in complex spinal cord injuries and sealing dural rupture
Authors: Shang Li, Yijian Guo, Xiaoyu Zhou, Can Li, Yatian Hong, Mingxin Li, Qingchen Zhang, Bin Ning, Yanyan Jiang
Journal: Biomaterials (2025)
DNA Hydrogels in Tissue Engineering: From Molecular Design to Next‐Generation Biomedical Applications
Authors: Ziyu Zhu, Yemu Yang, Yun Jiang, Tianyi Gu, Lixuen Siow, Yunxia Gao, Yuxin Zheng, Kuoran Xing, Siyi Zhou, Chuhan Zhang, Jiaxing Gong, Yu Liu, Mengfei Yu
Journal: Advanced Healthcare Materials (2025)

Abstract DNA hydrogels have emerged as promising materials in tissue engineering due to their biocompatibility, programmability, and responsiveness to stimuli. Synthesized through physical and chemical crosslinking, these hydrogels can be categorized into functionalized types, such as those based on aptamers, and stimuli‐responsive types that react to pH, temperature, and light. This review highlights their applications in tissue engineering, including drug delivery, cell culture, biosensing, and gene editing. DNA hydrogels can encapsulate therapeutic agents, support cell growth, and respond dynamically to environmental changes, making them ideal for tissue engineering. A comprehensive bibliometric analysis is included, identifying key research trends and emerging areas of interest in DNA hydrogel design, synthesis, and biomedical applications. The analysis provides a deeper understanding of the field's development and future research directions. Challenges such as mechanical strength, stability, and biosafety persist, but the integration of AI in hydrogel design shows promise for advancing their functionality in clinical applications.
Molecular Tools to Study and Control Dopaminergic Neurotransmission With Light
Authors: Galyna Maleeva, Carlo Matera, Silvia Roda, Alessio Colleoni, Marco De Amici, Pau Gorostiza
Journal: Medicinal Research Reviews (2025)

ABSTRACT Dopaminergic neurotransmission is involved in several important brain functions, such as motor control, learning, reward‐motivated behavior, and emotions. Dysfunctions of dopaminergic system may lead to the development of various neurological and psychiatric disorders, like Parkinson's disease, schizophrenia, depression, and addictions. Despite years of sustained research, it is not fully established how dopaminergic neurotransmission governs these important functions through a relatively small number of neurons that release dopamine. Light‐driven neurotechnologies, based on the use of small light‐regulated molecules or overexpression of light‐regulated proteins in neurons, have greatly contributed to the advancement of our understanding of dopaminergic circuits and our ability to control them selectively. Here, we overview the current state‐of‐the‐art of light‐driven control of dopaminergic neurotransmission. While we provide a concise guideline for the readers interested in pharmacological, pharmacogenetic, and optogenetic approaches to modulate dopaminergic neurotransmission, our primary focus is on the usage of photocaged and photo‐switchable small dopaminergic molecules. We argue that photopharmacology, photoswitchable molecules of varied modalities, can be employed in a wide range of experimental paradigms, providing unprecedent insights into the principles of dopaminergic control, and represent the most promising light‐based therapeutic approach for spatiotemporally precise correction of dopamine‐related neural functions and pathologies.
All-in-one extracellular matrix-based powders with instant self-assembly and multiple bioactivities integrate hemostasis and in-situ tissue functional repair
Authors: Chen-Yu Zou, Chen Han, Ming Xiong, Juan-Juan Hu, Yan-Lin Jiang, Xiu-Zhen Zhang, Ya-Xing Li, Long-Mei Zhao, Yu-Ting Song, Qing-Yi Zhang, Qian-Jin Li, Rong Nie, Yue-Qi Zhang, Jesse Li-Ling, Hui-Qi Xie
Journal: Bioactive Materials (2025)
Multicentric Retrospective Analysis of Oncocytic Adrenocortical Carcinoma: Insights into Clinical and Management Strategies
Authors: Antonio Prinzi, Valentina Guarnotta, Guido Di Dalmazi, Letizia Canu, Filippo Ceccato, Francesco Ferraù, Giuseppe Badalamenti, Manuela Albertelli, Maria Cristina De Martino, Giuseppe Fanciulli, Roberta Modica, Angelo Pani, Francesco Arcidiacono, Ignazio Barca, Francesca Donnarumma, Lorenzo Zanatta, Marianna Torchio, Ylenia Alessi, Chiara Vitiello, Francesco Frasca, Pasqualino Malandrino
Journal: Endocrine Pathology (2025)
Ovarian Function Restoration with Biomimetic Scaffold Incorporating Angiogenic Molecules and Antioxidant in Chemotherapy‐Induced Perimenopausal Model
Authors: Da‐Seul Kim, Dong Seok Jeong, So‐Yeon Park, Ji‐Won Jung, Jeoung Eun Lee, Jun‐Kyu Lee, Seung‐Woon Baek, Dong Ryul Lee, Dong Keun Han
Journal: Advanced Healthcare Materials (2025)

Abstract Chemotherapy‐induced premature ovarian insufficiency (POI) is a major cause of infertility and hormonal imbalance in young female cancer survivors. In this study, developed a biomimetic scaffold is developed that incorporates polydeoxyribonucleotide (PDRN) and melatonin to restore ovarian function. The scaffold is designed to mimic the ovarian extracellular matrix (ECM), enhancing angiogenesis, promoting antioxidant effects, and reducing reactive oxygen species (ROS). Human embryonic stem cell‐derived mesenchymal progenitor cells (hESC‐MPCs) are also incorporated to further support tissue regeneration. The scaffold demonstrated strong efficacy in improving cell survival, promoting folliculogenesis, and restoring ovarian function in a chemotherapy‐induced perimenopausal mouse model. Results showed that the scaffold enhanced vascularization, reduced fibrosis, and normalized hormone levels, including estrogen (E 2 ) and anti‐Müllerian hormone (Amh). Additionally, the transplantation of the scaffold restored fertility rates and increased the number of offspring in treated mice. This approach presents a promising solution for improving ovarian recovery and fertility preservation in patients with chemotherapy‐induced POI, offering a novel therapeutic strategy for reproductive health.
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the <scp>FINEARTS</scp>‐<scp>HF</scp> trial
Authors: Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray
Journal: European Journal of Heart Failure (2025)
<i>Faecalibacterium</i> in the Gut Microbiota Predicts Tolerance Acquisition in Pediatric Hen's Egg Allergy
Authors: Shohei Akagawa, Shoji Tsuji, Yoko Nakai, Chika Urakami, Mitsuru Yamagishi, Yuko Akagawa, Kazunari Kaneko
Journal: Allergy (2025)
Bioengineered metastatic cancer nanovaccine with a TLR7/8 agonist for needle-free intranasal immunization
Authors: Jae Min Jung, Min Sang Lee, Young Kyu Seo, Jung Eun Lee, Su Yeon Lim, Dahwun Kim, Siyan Lyu, Chaeeun Park, Byung Deok Kim, Ju Hwa Shin, Ji Hyun Lee, Pin Liu, Junku Jung, João Conde, Thavasyappan Thambi, Ji Hoon Jeong, Doo Sung Lee
Journal: Biomaterials (2025)
Evaluation of the efficacy and safety of different regimens for Helicobacter pylori eradication therapy during the COVID-19 pandemic and post-pandemic period in Ukraine: a retrospective observational study
Authors: V.V. Cherniavskyi, A.Ye. Baylo, L.S. Hvozdetska, V.V. Tishchenko, L.L. Pavlovskyi, D.O. Reshotko
Journal: GASTROENTEROLOGY (2025)

Background. COVID-19 pandemic has negatively affected treatment of H.pylori and has long-term consequences, in particular, bacterial susceptibility decrease to broad-spectrum antibiotics used for typical H.pylori eradication. Currently, there is limited scientific data on the effectiveness and safety of standard eradication regimens in the post-COVID period. The aim of the study is to investigate the effectiveness and safety of 10- and 14-day H.pylori eradication regimens used in 2022–2025 and to compare them with the effectiveness and safety of 10-day regimens used over 2019–2021 in Ukraine, as well as to identify the relationship between unsuccessful treatment cases and anamnestic data. Materials and methods. We conducted retrospective multicenter observational study for 2019–2025. A comparative analysis on the effectiveness and safety of various eradication regimens in group I (n = 82) and group II (n = 74) was performed. We determined frequency, intensity, and spectrum of side effects in both groups. A multivariate regression analysis of the relationship between unsuccessful treatment cases and anamnestic data was conducted. Results. Comparative analysis revealed no statistical difference in the eradication rates between groups I and II (p ≥ 0.05). The lowest eradication rate among patients in group II was detected on three-component regimens ESO + CA (67 %) and PANTO + CM/T (70 %). The highest eradication rate was on quadruple regimen ESO + LAF (100 %). In group II, the frequency of side effects, their intensity, and spectrum significantly increased after 14-day treatment (p &lt; 0.001) compared to group I. Regression analysis revealed that male gender, history of COVID-19 infection, and first treatment attempts were significantly more frequently associa­ted with unsuccessful treatment (p &lt; 0.05). Conclusions. Standard 14-day three-component H.pylori eradication regimens ESO + CA, PANTO + CM/T, PANTO + AM/T have unacceptable eradication rates (≤ 70 %). The 14-day quadruple ESO + LAF regimen demonstrates a high eradication rate (&gt; 90 %), but is accompanied by frequent and diverse side effects, reduced adherence to treatment. Treatment failure is significantly associated with male gender, previous COVID-19 infection, and first treatment attempts.
The impact of liver steatosis on the severity of COVID-19 in patients with chronic coronary syndrome
Authors: M.M. Zhaivoronok, S.Ye. Mostovyi, O.M. Safonova
Journal: GASTROENTEROLOGY (2025)

Background. The coronavirus disease 2019 (COVID-19) remains one of the most pressing global health issues today. According to contemporary literature, COVID-19 may trigger a deterioration of liver function in patients with or without pre-existing liver diseases. It is known that COVID-19 can lead to the reactivation of pre-existing liver conditions, such as metabolic dysfunction-associated steatotic liver disease (MASLD), causing its further progression to liver cirrhosis. Patients with chronic coronary syndrome (CCS) are most vulnerable to coronavirus disease and its complications (including MASLD). Therefore, prognostic ultrasound assessment of liver steatosis in terms of COVID-19 severity and complications is crucial. The aim of our study was to evaluate the impact of MASLD on the severity of COVID-19 in patients with chronic coronary syndrome. Materials and methods. In this study, we evaluated multidetector computed tomography (MDCT) scans of the liver from 120 patients (41 women, average age 63.73 years) who were referred for lung examination and had confirmed COVID-19 and CCS. We measured the attenuation values of the MDCT signal for the liver and spleen and calculated the liver-to-spleen ratio (LSR) to detect MASLD. Univariate and multivariate logistic regression analyses were used to identify independent early predictors of severe COVID-19 in patients with CCS. Results. Liver density and LSR in MASLD were significantly lower in patients who stayed in the intensive care unit. The prevalence of severe disease was higher in patients with CCS combined with MASLD than in the group without MASLD (odds ratio (OR) 3.512, 95% confidence interval (CI) 1.685–6.140, P &lt; 0.05). After adjusting for age and comorbidities, including diabetes, chronic obstructive pulmonary disease, and chronic kidney disease, multivariate logistic regression analysis indicated that MASLD is an independent risk factor for the severity of COVID-19 (OR 3.675, 95% CI 1.495–7.263, P = 0.020) in patients with CCS. Conclusions. MDCT of the liver during chest organ imaging plays a crucial role in the diagnosis of COVID-19 and can provide information regarding the disease prognosis. MASLD is an important marker of poor prognosis in patients with CCS and can be detected on MDCT through LSR assessment.
Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer
Authors: Ying Jiang, Zhiwen Qian, Cengzhu Wang, Danping Wu, Lu Liu, Xin Ning, Yilan You, Jie Mei, Xiaoqian Zhao, Yan Zhang
Journal: Journal for ImmunoTherapy of Cancer (2025)

Triple-negative breast cancer (TNBC) is the most malignant breast cancer, highlighting the need for effective immunotherapeutic targets. The immune checkpoint molecule B7-H3 has recently gained attention as a promising therapeutic target due to its pivotal role in promoting tumorigenesis and cancer progression. However, the therapeutic impact of B7-H3 inhibitors (B7-H3i) remains unclear. Transcriptomic and metabolomic analyses were conducted to explore the underlying mechanisms of B7-H3 inhibition in TNBC. The therapeutic efficacy of the combined treatment strategy was substantiated through comprehensive phenotypic assays conducted in vitro and validated in vivo using animal models. B7-H3 blockade induces a "primed for death" stress state in cancer cells, leading to distinct alterations in metabolic pathways. Specifically, B7-H3 knockdown activated the AKT signaling pathway and upregulated sterol regulatory element-binding protein 1 (SREBP1), which in turn elevated FASN expression. The simultaneous inhibition of both B7-H3 and FASN more effectively attenuated the malignant progression of TNBC. Our findings propose an "immune attack-metabolic compensation" dynamic model and suggest the feasibility of a dual-targeting strategy that concurrently inhibits both B7-H3 and FASN to enhance therapeutic efficacy in TNBC patients.